A PROSPECTIVE STUDY TO ANALYSE THE SIDE EFFECTS OF OLMESARTAN MEDOXOMIL AND ENALAPRIL IN HYPERTENSIVE SUBJECTS

Parminderpal Singh; Kiranjit Kiranjit

doi:10.22159/ajpcr.2018.v11i12.25460

Authors

Parminderpal Singh Department of General Medicine, GMC and Rajindra Hospital, Patiala, Punjab, India.
Kiranjit Kiranjit Department of Pulmonary Medicine, GGS Medical College, Faridkot, Punjab, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.25460

Keywords:

Coronary, Hypertension, Postural

Abstract

Objective: The present study was aimed to analyze the side effects of olmesartan medoxomil and enalapril in hypertensive subjects.

Methods: The study consisted of newly diagnosed hypertension categorized according to 7th report of Joint National Commission on prevention, detection, evaluation, and treatment of high blood pressure. The subjects were divided into two groups. The Group A subjects received olmesartan, and Group B subjects received enalapril. Pressure was recorded both in supine and sitting positions. The appearance of side effects was observed in the follow-up, i.e., dry cough, headache, postural hypotension, angioedema, dizziness, skin rashes, taste alterations, and urticaria. A statistical data were prepared on the basis of information obtained and analyzed thoroughly for antihypertensive effects and side effects of olmesartan and enalapril. SPSS software was used for analysis.

Results: There was observed an increase in the incidence of taste alteration with drug therapy in Group B (Enalapril). There was observed an increase in the incidence of postural hypotension with drug therapy in both groups. In Group A (Olmesartan), the incidence of postural hypotension at the beginning of trial, 4 weeks, and 8 weeks was 0%, 2%, and 2%, respectively. In Group A (Olmesartan), there was no incidence of a headache at the beginning of trial, at 4 weeks and 8 weeks.

Conclusion: From the study, it can be concluded that both olmesartan and enalapril are effective in Stage I and Stage II hypertension, but olmesartan is tolerated well with lesser side effects.

Downloads

Download data is not yet available.

Author Biographies

Parminderpal Singh, Department of General Medicine, GMC and Rajindra Hospital, Patiala, Punjab, India.

SENIOR RESIDENT, GMC AND RAJINDRA HOSPITAL, PATIALA, PUNJAB, INDIA.

Kiranjit Kiranjit, Department of Pulmonary Medicine, GGS Medical College, Faridkot, Punjab, India.

ASSOCIATE PROFESSOR, DEPARTMENT OF PULMONARY MEDICINE, GGS MEDICAL COLLEGE, FARIDKOT, PUNJAB, INDIA.

References

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.

Cornish KG, Joyner WL, Gilmore JP. Evidence for the conversion of angiotensin I to angiotensin II by the coronary microcirculation. Blood Vessels 1979;16:241-6.

Bernstein K, Martin BM, Bernstein EA, Linton J, Striker L, Striker G. The isolation of angiotensin converting enzyme cDNA. J Biol Chem 1988;263:1021-4.

Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995;40:141-4.

YeÅŸil S, YeÅŸil M, Bayata S, Postaci N. ACE inhibitors and cough. Angiology 1994;45:805-8.

Agostoni A, Cicardi M, Cungo M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999;44:21-5.

Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: Outcome after switching to a different treatment. Arch Intern Med 2004;164:910-3.

PÃ¼chler K, Nussberger J, Laeis P, Witte PU, Brunner HR. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997;15:1809-12.

Gomez HJ, Cirillo VJ, Smith SG 3rd. Enalapril: Benefit-to-risk ratio in hypertensive patients. J Cardiovasc Pharmacol 1990;15 Suppl 3:S26-9.

Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis. Eur Heart J 2014;35:1732-42.

Yoshida K, Kohzuki M. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cardiovasc Drug Rev 2004;22:285-308.

GaniyuKehinde A, Ismail AS. Assessment of antihypertensives utilization in a private teaching hospital in Nigeria. Int J Pharm Pharm Sci 2012;4:480-3.

Joshi UH, Ganatra TH, Desai TR, Tirgar PR. Evaluation of antihypertensive activity of Evolvulus alsinoides in adrenaline induced hypertensive rats. Int J Pharm Pharm Sci 2012;4:194-8.